Andrew Schwab Sells 400,000 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 400,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the transaction, the director owned 2,033,270 shares in the company, valued at $8,214,410.80. The trade was a 16.44% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CAMP4 Therapeutics Stock Down 4.6%

Shares of CAMP4 Therapeutics stock traded down $0.19 during trading hours on Monday, reaching $3.96. 190,269 shares of the company’s stock were exchanged, compared to its average volume of 187,803. The business has a fifty day moving average of $4.13 and a two-hundred day moving average of $4.36. The company has a market capitalization of $248.49 million, a P/E ratio of -1.71 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 1 year low of $1.41 and a 1 year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. As a group, research analysts predict that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Hedge funds have recently made changes to their positions in the stock. Bridgeway Capital Management LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth $36,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at $78,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at $115,000. Finally, Goldman Sachs Group Inc. acquired a new position in CAMP4 Therapeutics during the 4th quarter worth about $115,000.

Analysts Set New Price Targets

CAMP has been the topic of several recent research reports. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.56.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.